Vesper Bio bags Michael J Fox Foundation grant to assess sortilin inhibitor impact in Parkinson’s

Targeting sortilin to rebalance progranulin levels thought to hold promise in CNS diseases, including Parkinson’s.
Danish biotech Vesper Bio revealed it has been awarded a grant worth approximately $873,000 by The Michael J Fox Foundation for Par…Read More

Juvena gets FDA Orphan Drug nod for muscle regeneration therapy

Longevity biotech goes after rare muscle disease with plans to expand into diseases of aging, including sarcopenia.
Longevity biotech startup Juvena Therapeutics has been granted the FDA’s Orphan Drug designation for using its flagship drug candidate, JUV-161, to address M…Read More

‘Skinny jabs’ may be longevity drugs, but healthy people shouldn’t be taking them
Leading GLP-1 researcher says while drugs like semaglutide do appear to have longevity benefits, they won’t make healthy people healthier.
Semaglutide, the so called “skinny jab”, marketed around the world as Wegovy, Ozempic and Rybelsus, is rarely out of the news…Read More

Reprogrammed T cells can eliminate senescent cells, new research shows

Single treatment CAR T cell therapy reduces age-related decline in mice and can protect against diabetes and obesity.
Researchers have discovered that T cells, a type of white blood cells, can be reprogrammed to seek out and destroy senescent cells.

Longevity.Technology:…Read More

The gut microbiome: A key to unlocking healthy aging
Gut health has huge implications for healthspan and longevity, and could hold the key to improving cognition, immunity and healthy aging.
You are not alone… in fact you have more than 100 trillion companions residing in your gut forming the microbiome. The intricate relationship between the h…Read More

Loyal launches pivotal dog lifespan extension trial

First dog dosed in study designed to demonstrate lifespan and healthspan extension in 1,000 senior dogs.
Longevity biotech company Loyal has initiated a clinical trial in the US for a drug designed to extend the healthy lifespan of senior dogs. The pivotal STAY study, involving over 1,000…Read More

Catalyzing a change in how we treat Alzheimer’s

Covalent Bioscience’s Stephanie Planque explains why longevity therapies should be converting to catalytic antibodies.
Covalent Bioscience was formed by Richard Massey, Sudhir Paul and Stephanie Planque to leverage catalytic antibody tech for unmet medical needs. Catalytic antibodies (so…Read More

Fractyl raises $110m IPO, nominates GLP-1 gene therapy candidate

Obesity drug developer plots path to human trials following NASDAQ debut in challenging IPO market.
Metabolic therapeutics company Fractyl Health raised $110 million in its initial public offering last week. The company, which floated on the NASDAQ under the symbol GUTS, has…Read More

New research supports therapeutic potential of senolytics in DME
Publication in Nature Medicine details long-lasting, disease-modifying intervention in vision loss from diabetic macular edema.
UNITY Biotechnology, a company working on therapeutics to slow, halt or reverse diseases of aging, today announced new research published in the…Read More